DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-19.24%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$384M
AUM Growth
-$13.9M
Cap. Flow
+$77.9M
Cap. Flow %
20.3%
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4
Avg Time Held
2 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.9 years

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24.9M
2
IBB icon
iShares Biotechnology ETF
IBB
+$8.02M
3
FATE icon
Fate Therapeutics
FATE
+$4.99M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$4.59M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.37M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.1M
2
OTIC
Otonomy, Inc.
OTIC
+$1.49M
3
HOOK icon
HOOKIPA Pharma
HOOK
+$747K
4
PRQR icon
ProQR Therapeutics
PRQR
+$685K
5
XENE icon
Xenon Pharmaceuticals
XENE
+$674K

Sector Composition

Rank Sector Weight
1 Healthcare 88.84%
2 Miscellaneous 11.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STXS icon
1
Stereotaxis
STXS
$104M
$51M 13.3%
13,680,554
– –
2013 Q2
35 quarters
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$9.68B
$24.2M 6.31%
+269,500
New +$24.9M
2022 Q1
0 quarters
FATE icon
3
Fate Therapeutics
FATE
$231M
$19.4M 5.06%
500,930
+128,770
+35% +$4.99M
2019 Q2
11 quarters
BPMC icon
4
DELISTED
Blueprint Medicines
BPMC
$15.7M 4.1%
246,280
+39,369
+19% +$2.83M
2016 Q4
21 quarters
ACET icon
5
Adicet Bio
ACET
$45.6M
$14.3M 3.73%
44,742
-1,081
-2% -$249K
2020 Q3
6 quarters
IBB icon
6
iShares Biotechnology ETF
IBB
$10.4B
$13.4M 3.48%
102,500
+61,600
+151% +$8.02M
2016 Q4
21 quarters
XENE icon
7
Xenon Pharmaceuticals
XENE
$3.27B
$11.6M 3.03%
380,163
-22,504
-6% -$674K
2015 Q3
26 quarters
KRTX icon
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10.4M 2.71%
82,053
+9,630
+13% +$1.08M
2020 Q1
8 quarters
DXCM icon
9
DexCom
DXCM
$31.5B
$9.28M 2.42%
72,552
– –
2017 Q3
18 quarters
BHVN icon
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.2M 2.4%
77,600
+19,500
+34% +$2.43M
2018 Q2
15 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$13.8B
$7.84M 2.04%
83,655
– –
2016 Q1
24 quarters
CYTK icon
12
Cytokinetics
CYTK
$8.81B
$7.79M 2.03%
211,495
+77,401
+58% +$2.75M
2021 Q3
2 quarters
NRIX icon
13
Nurix Therapeutics
NRIX
$2.58B
$7.61M 1.98%
543,344
+237,024
+77% +$4.21M
2021 Q1
4 quarters
MORF icon
14
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.29M 1.9%
181,467
– –
2020 Q4
5 quarters
CSII
15
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.49M 1.69%
286,988
– –
2018 Q2
15 quarters
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.21B
$6.46M 1.68%
371,987
+75,452
+25% +$1.27M
2020 Q2
7 quarters
MRUS icon
17
DELISTED
Merus
MRUS
$6.21M 1.62%
234,989
+8,900
+4% +$239K
2021 Q1
4 quarters
SAGE icon
18
DELISTED
Sage Therapeutics
SAGE
$5.97M 1.56%
180,306
– –
2017 Q4
17 quarters
RVMD icon
19
Revolution Medicines
RVMD
$41.4B
$5.92M 1.54%
232,101
+19,870
+9% +$432K
2020 Q4
5 quarters
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.26B
$5.48M 1.43%
490,061
+30,000
+7% +$442K
2020 Q3
6 quarters
CBAY icon
21
DELISTED
Cymabay Therapeutics
CBAY
$5.26M 1.37%
1,692,569
-95,000
-5% -$299K
2021 Q1
4 quarters
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.02M 1.31%
298,476
+22,500
+8% +$333K
2020 Q2
7 quarters
NTUS
23
DELISTED
Natus Medical Inc
NTUS
$5.01M 1.31%
190,635
– –
2017 Q2
19 quarters
APLS icon
24
DELISTED
Apellis Pharmaceuticals
APLS
$4.77M 1.24%
+93,935
New +$4.15M
2022 Q1
0 quarters
ATRC icon
25
AtriCure
ATRC
$2.91B
$4.73M 1.23%
72,029
– –
2013 Q2
35 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, DAFNA Capital Management held 98 positions worth $384M, down 3.5% from $398M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $77.9M of net new capital in Q1 2022, opening 11 new positions and adding to 36 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Otonomy, Inc., an estimated $1.49M trimmed.

  • DAFNA Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q1 2022, an estimated $8.02M increase.
  • DAFNA Capital Management's biggest Q1 2022 reduction was Otonomy, Inc., cutting an estimated $1.49M.
  • DAFNA Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $11.1M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $384M portfolio in Q1 2022.
  • DAFNA Capital Management opened 11 new positions and closed 4 in Q1 2022.
  • DAFNA Capital Management's portfolio value fell 3.5% quarter-over-quarter to $384M.

Based on DAFNA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.